Pueraria mirifica for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Pueraria mirifica for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A Thai root whose compounds act much like the body's own estrogen. The firmest finding is local: vaginal tissue recovers its mature cell layer, and dryness and pain ease. Wider claims — hot flushes, cholesterol, bone loss — rest on studies mostly lacking a dummy-treatment comparison. Breast enlargement was never tested in a controlled study. Safety is unsettled; batch strength varies widely. (Full Review)

Protocol

Standard oral protocol
20–50 mg root powder daily
Dried root powder once daily, taken in the morning. Higher doses have no demonstrated added benefit.
Local genitourinary protocol
0.5 g of 5–6% vaginal gel
Applied intravaginally daily for two weeks, then three times weekly for ten weeks.
Competing extract protocol
200 mg root extract twice daily
Standardised to 150 mcg miroestrol. The two approaches have never been compared.
Time to effect
Vaginal dryness
About 12 weeks
Oral use; tissue maturation follows after 24 weeks.
Climacteric symptom scores
One month
Scores fell measurably by this point.
Lipid changes
Two months
Seen in one trial; a second found no lipid benefit.

Benefits

Contraindications
  • Current or past estrogen-receptor-positive breast cancer, endometrial cancer, or endometrial hyperplasia with atypia
  • Undiagnosed abnormal vaginal bleeding, until the cause is established
  • Personal or first-degree family history of congenital long QT syndrome, or a known KCNQ1, KCNH2, or SCN5A variant
  • History of venous thromboembolism, or a known clotting-factor variant such as factor V Leiden
  • Active liver disease, cholestasis, or Child-Pugh Class B or C cirrhosis
  • Pregnancy or breastfeeding
  • Premenopausal women and adolescents seeking breast enlargement
  • Men
  • Selective estrogen receptor modulators (tamoxifen, raloxifene) during breast-cancer treatment
  • Aromatase inhibitors (anastrozole, letrozole, exemestane)
    •
Key Interactions
  • Oral estrogen and menopausal hormone therapy (estradiol, conjugated equine estrogen)
  • Combined oral contraceptives
  • Warfarin and other vitamin K antagonists
  • Drugs that prolong the QT interval (amiodarone, sotalol, citalopram, ondansetron)
  • CYP1A2 substrates (caffeine, theophylline, clozapine, olanzapine)
  • Drugs cleared through bile (statins, methotrexate, some antibiotics)
  • Over-the-counter anti-inflammatory painkillers (ibuprofen, naproxen, aspirin)
  • Over-the-counter cimetidine for heartburn
  • Soy isoflavones, red clover, black cohosh, hops, and flaxseed lignans
  • Levothyroxine and thyroid therapy
  • Vaginal laser or radiofrequency therapy for genitourinary symptoms
    •

Risk & Side Effects

  • High: Irregular vaginal bleeding and menstrual disturbance; unpredictable estrogenic potency between products
  • Medium: Breast tenderness and swelling; estrogenic stimulation of endometrium and breast tissue; rise in C-reactive protein
  • Low: Liver and blood count abnormalities; ovarian cycle suppression in premenopausal users
  • Speculative: QT prolongation in genetically susceptible people; chromosomal damage at high doses; impaired sperm motility in men

Monitoring

Marker Target Why
Follicle-stimulating hormone Postmenopausal baseline typically >30 IU/L; a fall of 20–30% Confirms the preparation is biologically active systemically
Luteinising hormone No established target; track the fall from own baseline Second confirmation of pituitary feedback; divergence suggests assay noise
Estradiol No target; track change from own baseline Detects unexpected endogenous estrogen, which changes the risk calculus
Endometrial thickness (transvaginal ultrasound) <4 mm postmenopausal; <5 mm is the usual action threshold The direct measure of the principal risk in women with a uterus
Low-density lipoprotein cholesterol <100 mg/dL; <70 mg/dL where cardiovascular risk is elevated Tracks the claimed lipid benefit, which is conflicted between trials
High-density lipoprotein cholesterol >60 mg/dL in women The endpoint that moved most in the positive lipid trial
Triglycerides <100 mg/dL Both arms of one trial rose 15%, so a rise is not necessarily drug-related
High-sensitivity C-reactive protein <1.0 mg/L Pooled trial data show this marker roughly doubling on treatment
Alanine aminotransferase and alkaline phosphatase ALT <25 U/L in women; alkaline phosphatase 50–90 U/L Covers the transient liver abnormalities and the animal bile-transporter signal
Haemoglobin and full blood count Haemoglobin 12.5–15.0 g/dL in women Transient anaemia occurred in early dosing work, and bleeding is the top reported harm
Thyroid-stimulating hormone 0.5–2.0 mIU/L Oral estrogenic load can raise thyroid hormone binding and unmask under-replacement
Vaginal pH 3.8–4.5 Cheap, immediate readout of vaginal epithelial maturation

Cadence: Baseline panels before starting, plus transvaginal ultrasound where the uterus is intact. Liver panel and full blood count repeat at 8–12 weeks; hormone, lipid, and inflammation markers at 3 and 6 months. Beyond six months with an intact uterus, endometrial ultrasound repeats annually.

Qualitative Assessment

  • Frequency and intensity of hot flushes and night sweats, counted rather than estimated
  • Vaginal dryness, burning, and pain with intercourse
  • Sleep continuity — number of awakenings, not just total hours
  • Mood stability and irritability
  • Breast tenderness, swelling, or any new lump
  • Any vaginal bleeding or spotting, with dates
  • Skin dryness and general sense of vitality, the original traditional endpoints
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.